secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-057115
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing
--------------------------------------------------------------------------------

- Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
- Cash, equivalents and marketable securities $171.7M; runway expected into 2028.
- VY1706 tau silencing gene therapy: IND-enabling GLP tox completed; FDA IND on track for Q2, first-in-human dosing H2 2026.
- VY7523 anti-tau antibody: tau PET imaging efficacy data from MAD trial expected H2 2026.
- Neurocrine's NBIB-'223 for Friedreich's ataxia: GLP tox completed, FDA orphan drug designation; clinical trial H2 2026 pending IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/0001104659-26-057115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465926057115/vygr-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer